HOME >> BIOLOGY >> NEWS
MIT creates 3-D scaffold for growing stem cells

d to and supported by the cells, other structures and proteins around them. A cell's normal environment is a complex network of tiny fibers, gaps and pores through which oxygen, hormones and nutrients are delivered and waste products filtered away. Cells move within their natural environments in response to chemical signals or other stimuli.

Researchers are aware that cells on flat surfaces have skewed metabolisms, gene expression and growing patterns. But the only choices have been glass labware and a product called Matrigel, a gelatinous protein mixture secreted by mouse tumor cells. While Matrigel does resemble a complex extracellular environment, it also contains growth factors and unknown proteins that limit its desirability for experiments requiring precise conditions.

"Synthetic biopolymer microfiber scaffolds have been studied for more than 30 years to mimic a living 3D microenvironment, but concerns exist about their degradation products and chemicals," the authors wrote in the paper.

Other synthetic polymer biomaterials are simply too big. Getting cells to grow on them is like forcing spiders to build webs on skyscraper girders. Zhang's nanofiber scaffold, around 1,000 times smaller than the existing systems, is much closer in size to the extracellular matrices that living cells manufacture themselves.

Adding motifs

With the addition of defined amino acid fragments called active motifs, the scaffold can be fashioned to coax stem cells to behave in certain desirable ways-such as differentiating into needed body tissues or migrating toward bone marrow and other natural destinations.

"What makes these designer scaffolds particularly interesting is that cells survive longer and differentiate better without additional soluble growth factors," Zhang said. "This suggests that extracellular microenvironments may play a more important role for cell survival and for carrying out cell functions than previ
'"/>

Contact: Elizabeth A. Thomson
thomson@mit.edu
617-258-5402
Public Library of Science
26-Dec-2006


Page: 1 2 3

Related biology news :

1. MIT creates 3-D images of living cell
2. Fusing imaging technologies creates synergy, helps diagnose heart disease accurately
3. Harvard team creates spray drying technique for TB vaccine
4. How badger culling creates conditions for spread of bovine TB
5. Climate change creates dramatic decline in red-winged black bird population
6. Purdue creates new low-cost system to detect bacteria
7. Brazil creates buffer zone around coral reefs off Atlantic coast
8. Penn researchers discover gene that creates second skeleton
9. Student creates material with multi-patterned surface to study tissue growth
10. Enzyme action creates protein linked to Alzheimers disease
11. Device creates electricity and treats wastewater

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MIT creates scaffold for growing stem cells

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: